- Faron Appoints Maija HollmÃ©n PhD as CSO
- Amendment Terms and Conditions with IPF Partners
- Faron Announces Poster Presentation at SITC
- BEXMAB Study Update
- Holding(s) in Company
- Faron Announces Melanoma Cohort Data from MATINS
- Results of Placing
- Proposed Issue and Placing of Shares
- Grant of Options
- Top-Line Data on Bexmarilimab Dose Variation
SmartText not available for this item.
4.02Apr 24 20204.53Apr 21 2020
Markit short selling activity
|Market cap||168.74m GBP|
|EPS (TTM)||-0.3876 |
Data delayed at least 15 minutes, as of Apr 24 2020 12:00 BST.